FORBES-TATE

Lobbying for ALEXION PHARMACEUTICALS, INC. · Biopharmaceutical Company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · House · Senate · $50,000.00 income · posted Oct 19, 2025

Lobbying activity 2

Health Issues

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to low-volume Diagnosis Related Groups (DRG); Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.

Medicare/Medicaid

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.